Switching from Posaconazole Suspension to Tablets Increased Serum Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity.
Antimicrob Agents Chemother. 2014 Sep 8;
Authors: Jung DS, Tverdek FP, Kontoyiannis DP
We evaluated posaconazole serum concentrations and hepatotoxicity in 12 leukemia patients who transitioned from posaconazole suspension to tablets. Patients switched to tablets had significantly increased posaconazole concentrations (median, suspension 748 ng/mL; tablet 1910 ng/mL, P < .01) without clinically relevant hepatotoxicity.
PMID: 25199774 [PubMed - as supplied by publisher]